1
|
Nowell PC and Hungerford DA: A minute
chromosome in human chronic granulocyte leukeamia. Science.
132:1497–1501. 1960.
|
2
|
Melo JV: The diversity of BCR-ABL fusion
proteins and their relationship to leukemia phenotype. Blood.
88:2375–2384. 1996.PubMed/NCBI
|
3
|
Calabretta B and Perrotti D: The biology
of CML blast crisis. Blood. 103:4010–4022. 2004. View Article : Google Scholar : PubMed/NCBI
|
4
|
Quentmeier H, Eberth S, Romani J, Zaborski
M and Drexler HG: BCR-ABL1-independent PI3Kinase activation causing
imatinib-resistance. J Hematol Oncol. 4:62011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Cortes J, O’Brien S and Kantarjian H:
Discontinuation of imatinib therapy after achieving a molecular
response. Blood. 104:2204–2205. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Crowley LC, Elzinga BM, O’Sullivan GC and
McKenna SL: Autophagy induction by Bcr-Abl-expressing cells
facilitates their recovery from a targeted or nontargeted
treatment. Am J Hematol. 86:38–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Bellodi C, Lidonnici MR, Hamilton A, et
al: Targeting autophagy potentiates tyrosine kinase
inhibitor-induced cell death in Philadelphia chromosome-positive
cells, including primary CML stem cells. J Clin Invest.
119:1109–1123. 2009. View
Article : Google Scholar
|
8
|
Mizushima N: Autophagy: process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar
|
9
|
Degtyarev M, De Maziere A, Orr C, et al:
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors
to lysosomotropic agents. J Cell Biol. 183:101–116. 2008.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Holyoakes T; Medical Research Council.
Research Portofolio: A randomised phase II trial of IM versus
HCQ/IM for patients with CML in MCyR with residual disease by
Q-PCR. http://www.mrc.ac.uk/ResearchPortfolio/Grant/Record.htm?GrantRef=G0900882&CaseId=15301.
|
11
|
Eskelinen EL, Prescott AR, Cooper J, et
al: Inhibition of autophagy in mitotic animal cells. Traffic.
3:878–893. 2002. View Article : Google Scholar : PubMed/NCBI
|
12
|
Groth-Pedersen L, Ostenfeld MS,
Hoyer-Hansen M, Nylandsted J and Jaattela M: Vincristine induces
dramatic lysosomal changes and sensitizes cancer cells to
lysosome-destabilizing siramesine. Cancer Res. 67:2217–2225. 2007.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Vetterlein M, Niapir M, Ellinger A,
Neumüller J and Pavelka M: Brefeldin A-regulated retrograde
transport into the endoplasmic reticulum of internalised wheat germ
agglutinin. Histochem Cell Biol. 120:121–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Nishida Y, Arakawa S, Fujitani K, et al:
Discovery of Atg5/Atg7-independent alternative macroautophagy.
Nature. 461:654–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Aguayo A and Couban S: State-of-the-art in
the management of chronic myelogenous leukemia in the era of the
tyrosine kinase inhibitors: evolutionary trends in diagnosis,
monitoring and treatment. Leuk Lymphoma. 50(Suppl 2): 1–8. 2009.
View Article : Google Scholar
|
16
|
O’Brien SG, Guilhot F, Goldman JM, et al:
International randomized study of interferon versus STI571 (IRIS)
7-year follow-up: sustained survival, low rate of transformation
and increased rate of major molecular response (MMR) in patients
(pts) with newly diagnosed chronic myeloid leukemia in chronic
phase (CMLCP) treated with imatinib (IM). (ASH Annual Meeting
Abstracts). Blood. 112:1862008.
|
17
|
Amaravadi RK, Lippincott-Schwartz J, Yin
X-M, et al: Principles and current strategies for targeting
autophagy for cancer treatment. Clin Cancer Res. 17:654–666. 2011.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Lassen U, Kristjansen PE, Osterlind K, et
al: Superiority of cisplatin or carboplatin in combination with
teniposide and vincristine in the induction chemotherapy of
small-cell lung cancer. A randomized trial with 5 years follow up.
Ann Oncol. 7:365–371. 1996.PubMed/NCBI
|
19
|
Pommepuy I, Terro F, Petit B, et al:
Brefeldin A induces apoptosis and cell cycle blockade in
glioblastoma cell lines. Oncology. 64:459–467. 2003. View Article : Google Scholar : PubMed/NCBI
|
20
|
Chapman JR, Tazaki H, Mallouh C and Konno
S: Brefeldin A-induced apoptosis in prostatic cancer DU-145 cells:
a possible p53-independent death pathway. BJU Int. 83:703–708.
1999. View Article : Google Scholar : PubMed/NCBI
|
21
|
Larsson DE, Wickström M, Hassan S, OBerg K
and Granberg DAN: The cytotoxic agents NSC-95397, brefeldin A,
bortezomib and sanguinarine induce apoptosis in neuroendocrine
tumors in vitro. Anticancer Res. 30:149–156. 2010.PubMed/NCBI
|
22
|
Fox BM, Vroman JA, Fanwick PE and Cushman
M: Preparation and evaluation of sulfide derivatives of the
antibiotic brefeldin A as potential prodrug candidates with
enhanced aqueous solubilities. J Med Chem. 44:3915–3924. 2001.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Phillips LR, Wolfe TL, Malspeis L and
Supko JG: Analysis of brefeldin A and the prodrug breflate in
plasma by gas chromatography with mass selective detection. J Pharm
Biomed Anal. 16:1301–1309. 1998. View Article : Google Scholar : PubMed/NCBI
|
24
|
Anadu NO, Davisson VJ and Cushman M:
Synthesis and anticancer activity of brefeldin A ester derivatives.
J Med Chem. 49:3897–3905. 2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Kamitsuji Y, Kuroda J, Kimura S, et al:
The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and
different modes of cell death execution in Bcr-Abl-positive
leukemias. Cell Death Differ. 15:1712–1722. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Carew JS, Nawrocki ST, Kahue CN, et al:
Targeting autophagy augments the anticancer activity of the histone
deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug
resistance. Blood. 110:313–322. 2007. View Article : Google Scholar : PubMed/NCBI
|
27
|
Qadir MA, Kwok B, Dragowska WH, et al:
Macroautophagy inhibition sensitizes tamoxifen-resistant breast
cancer cells and enhances mitochondrial depolarization. Breast
Cancer Res Treat. 112:389–403. 2008. View Article : Google Scholar
|
28
|
Ullen A, Farnebo M, Thyrell L, et al:
Sorafenib induces apoptosis and autophagy in prostate cancer cells
in vitro. Int J Oncol. 37:15–20. 2010. View Article : Google Scholar
|
29
|
O’Donovan TR, O’Sullivan GC and McKenna
SL: Induction of autophagy by drug-resistant esophageal cancer
cells promotes their survival and recovery following treatment with
chemotherapeutics. Autophagy. 7:509–524. 2011.PubMed/NCBI
|
30
|
Mortensen M, Soilleux EJ, Djordjevic G, et
al: The autophagy protein Atg7 is essential for hematopoietic stem
cell maintenance. J Exp Med. 208:455–467. 2011. View Article : Google Scholar : PubMed/NCBI
|